Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...
Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...
Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment. The stock was up 78% to $15.60 on Wednesday and was briefly paused ...
The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.
For decades, chronic disease management in Medicare has been hampered by a fee-for-service payment system that rewards volume and activity rather than true clinical improvement. This model created ...
Omeros (OMER) announced that the U.S. Food and Drug Administration, FDA, has approved YARTEMLE for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, TA-TMA, a ...
The field of exercise science is rapidly evolving through the integration of omics technologies, giving rise to promising subdisciplines such as enduromics ...
The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).
A conserved signaling axis linking Drosophila adipose tissue to nephrocyte function reveals how obesity can drive kidney dysfunction and points to new opportunities for therapeutic intervention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback